Randall Bateman, MD, director of the Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), an ongoing international clinical trial to evaluate experimental Alzheimer’s drugs, speaks with DIAN-TU participant Taylor Hutton. One of the drugs tested in the DIAN-TU, gantenerumab, improved biomarkers of disease despite unclear cognitive effects, prompting study leaders to offer participants the option of continuing to receive the drug and participate in follow-up examinations as part of a so-called open label extension. Credit: Matt Miller
An investigational Alzheimer’s drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3 clinical trial led by researchers at Washington University School…
Efesbet, kullanıcı dostu bir platform sunarak oyuncuların rahatça bahis yapmalarını ve kazanç elde etmelerini sağlar. Kazandıran içeriklerle dolu platformlar, oyun severlerin ilk tercihleri arasında...
Bahis severler, en iyi platformlar sayesinde hızlı ödemeler ve cazip bonuslarla daha verimli bir oyun deneyimi yaşar. Kullanıcılar, platformların sunduğu deneme bonuslarıyla oyun dünyasına...
